期刊文献+

含水核载牛血清白蛋白聚氰基丙烯酸丁酯微囊的制备及体外释放 被引量:3

PREPARATION AND IN VITRO RELEASE OF POLY(BUTYL CYANOACRYLATE) NANOCAPSULES WITH AN AQUEOUS CORE CONTAINING BOVINE SERUM ALBUMIN
在线阅读 下载PDF
导出
摘要 利用界面乳液聚合方法制备了新型含水核载牛血清白蛋白 (BSA)的聚氰基丙烯酸丁酯 (PBCA)纳米微囊 .分别研究了纳米微囊的粒径及其分布 ,表面Zeta电势的变化 .并以牛血清白蛋白为模型药物考察了药物包裹率和载药量的变化以及载药纳米微囊在磷酸缓冲溶液中的体外释放行为 .结果表明 ,所制备的纳米微囊平均粒径为 2 0 0nm ,多分散度为 0 2 2 6;表面Zeta电势的变化证明了BSA是包裹于纳米微囊的内部而不是吸附在其表面 ;包裹率和载药量取决于水相中BSA的初始浓度 ,当BSA的浓度为 0 8mg mL时 ,包裹率和载药量分别为 3 5 %和 0 485× 1 0 - 9mol mg;药物的释放速率取决于纳米微囊的壁厚 。 Poly(butyl cyanoacrylate) (PBCA) nanocapsules with an aqueous core containing bovine serum albumin (BSA) were prepared by interfacial polymerization in a W/O emulsion. The nanocapsule sizes and their distribution were measured by laser scattering technique and transmission electron micrography. The change of Zeta potential, encapsulation efficiency, drug loading and in vitro release of nanocapsules were investigated using BSA as a model drug. The experimental results showed that nanocapsules were approximately 200 nm in diameters, 0.226 in polydispersity. Encapsulation efficiency and drug loading were depended on the initial BSA concentration in aqueous phase. When the concentration was 0.8 mg/mL, encapsulation efficiency and drug loading were 35% and 0.485 x 10(-9)mol/mg of polymer. With the increase in the wall thickness of nanocapsules, the release time of BSA in PBS solution increased. The release rate could be controlled through adjusting the wall thickness of nanocapsules.
出处 《高分子学报》 SCIE CAS CSCD 北大核心 2003年第5期679-682,共4页 Acta Polymerica Sinica
基金 中国科学院院长特别基金资助项目 四川省杰出青年基金资助项目
  • 相关文献

参考文献10

  • 1冯鹏,马建标,王亦农,何炳林.界面聚合法制备聚α-氰基丙烯酸正丁酯毫微囊[J].高分子学报,2000,10(5):620-625. 被引量:18
  • 2Langer R.Nature, 1998,392:5 - 10.
  • 3Hideki M,Masao K,Hirofumi T,Yoshiaki K.Int J Pharm, 1999,187:143 - 152.
  • 4Takeuchl H, Yamamoto H, Kawashima Y. Advanced Drug Delivery Reviews, 2001,47 ( 1 ) : 39 - 54.
  • 5Fresta M,Cavailaro G,Wehrli E,Puglisi G.Biomter,1996,17:751 - 758.
  • 6Fattal E, Vauthier C, Aynie I, Nakada Y, Lambert G, Malvy C, Patrick C. J Controlled Release, 1998,53:137 - 143.
  • 7Fessi H, Puisieux F, Devissaguet J P, Ammoury N, Benita S. Int J Pharm, 1989,55:R1-R4.
  • 8Quintaner-Guerrero D, Allemann E, Doelker E, Fessi H. Pharm Res, 1998,15 : 1056 - 1062.
  • 9Vranckx H, Demoustier M,Deleers M. Eur J Pharm Biopharm, 1996,42:345 - 347.
  • 10Lenaerts V, Couvreur P, Christiaens E, Joiris E, Roland M. Biomater, 1984,5 : 65 - 68.

二级参考文献10

  • 1SeijoB,FattalE,Roblot TreupelL,CouvreurP. IntJPhyarm . 1990
  • 2Damgec,MichelC,AprahamianM,CouvreurP. AdvBiomater . 1987
  • 3KanteB,CouvreurP,Dubois KrackG,DeMeesterC,GuiotP,olandM,MercierM,SpeiserP. JPhyarmSci . 1982
  • 4KreuterJ,SchererD,MoorenFC,KinneRKH. ProcIntSympContrRelBioactMater ,19th . 1992
  • 5Bapat N,Boroujerdi M. Drug Development and Industrial Pharmacy . 1992
  • 6Damge C,Michel C,Aprahamian M,Couvreur P,Devissaguet J P. Journal of Controlled Release . 1990
  • 7Lowe P J,Temple C S. JPharm Pharmacol . 1994
  • 8Couvereur P,Vouthier C. Journal of Controlled Release . 1991
  • 9Damge C,Michel C,Aprahamian M,Couvreur P. Diabetes . 1988
  • 10Scherer D,Mooren F C,Kinne R K H,Kreuter J. Journal of Drug Targeting . 1993

共引文献17

同被引文献85

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部